Terms: = Pancreatic cancer AND CgA
221 results:
1. Plasma tryptophan pathway metabolites quantified by liquid chromatography-tandem mass spectrometry as biomarkers in neuroendocrine tumor patients.
Johansen SU; Hansen T; Nordborg A; Meyer R; Goll R; Florholmen J; Jensen E
J Neuroendocrinol; 2024 Mar; 36(3):e13372. PubMed ID: 38361341
[TBL] [Abstract] [Full Text] [Related]
2. Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM.
Ingenerf M; Karim H; Auernhammer C; Zacherl M; Wenter V; Winkelmann M; Ricke J; Berger F; Schmid-Tannwald C
Radiol Oncol; 2023 Dec; 57(4):436-445. PubMed ID: 38038419
[TBL] [Abstract] [Full Text] [Related]
3. Biomarkers in neuroendocrine neoplasms.
Zouli C; Zisimopoulou E; Chrisoulidou A
Hell J Nucl Med; 2023; 26 Suppl():44-48. PubMed ID: 37658563
[TBL] [Abstract] [Full Text] [Related]
4. Gene expression profile of hiPSC-derived cells differentiated with growth factors, forskolin and conditioned medium from human adrenocortical cell line.
Stelcer E; Jopek K; Blatkiewicz M; Olechnowicz A; Kamiński K; Szyszka M; Suchorska WM; Ruciński M
Adv Clin Exp Med; 2024 Apr; 33(4):397-407. PubMed ID: 37540158
[TBL] [Abstract] [Full Text] [Related]
5. [Expression and significance of INSM1 and SOX11 in pancreatic neuroendocrine tumor and solid pseudopapillary neoplasm].
Cao Z; Cen HB; Zhao JH; Mei J; Qin LZ; Liao W; Ao QL
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 55(4):575-581. PubMed ID: 37534634
[TBL] [Abstract] [Full Text] [Related]
6. Reappraisal of Malignant Risk Assessment for Small (≤20 mm) Non-functioning pancreatic Neuroendocrine Tumors.
Nanno Y; Toyama H; Matsumoto I; Uemura J; Asari S; Goto T; Lee D; Murakami T; Komatsu S; Yanagimoto H; Kido M; Ajiki T; Okano K; Takeyama Y; Fukumoto T
Ann Surg Oncol; 2023 Jun; 30(6):3493-3500. PubMed ID: 36795254
[TBL] [Abstract] [Full Text] [Related]
7. EMT Molecular Signatures of pancreatic Neuroendocrine Neoplasms.
Venugopal A; Michalczyk A; Khasraw M; Ackland ML
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362433
[TBL] [Abstract] [Full Text] [Related]
8. Co-Expression of Adaptor Protein FAM159B with Different Markers for Neuroendocrine Cells: An Immunocytochemical and Immunohistochemical Study.
Beyer AL; Kaemmerer D; Sänger J; Lupp A
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362289
[TBL] [Abstract] [Full Text] [Related]
9. The immunomodulatory functions of chromogranin A-derived peptide pancreastatin.
Ioannidis M; Mahata SK; van den Bogaart G
Peptides; 2022 Dec; 158():170893. PubMed ID: 36244579
[TBL] [Abstract] [Full Text] [Related]
10. [Pediatric pancreatic lesions: a clinicopathological analysis of 42 cases].
Gao Q; Xu H; Wang FH; Yi P; Yang TY; Li LP; Xia JQ; Zeng RX; Niu HL
Zhonghua Bing Li Xue Za Zhi; 2022 Sep; 51(9):861-867. PubMed ID: 36097903
[No Abstract] [Full Text] [Related]
11. Role of chromogranin A-derived fragments after resection of nonfunctioning pancreatic neuroendocrine tumors.
Andreasi V; Partelli S; Manzoni MF; Muffatti F; Di Filippo L; Crippa S; Corti A; Falconi M
J Endocrinol Invest; 2022 Jun; 45(6):1209-1217. PubMed ID: 35122631
[TBL] [Abstract] [Full Text] [Related]
12. Chromogranin A (cga) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Konka M; Chrapowicki E; Ćwikła JB
Med Clin (Barc); 2022 Jul; 159(2):85-89. PubMed ID: 34736622
[TBL] [Abstract] [Full Text] [Related]
13. Anticancer Effects of the
Tosoc JPS; Nuñeza OM; Sudha T; Darwish NHE; Mousa SA
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641577
[No Abstract] [Full Text] [Related]
14. [Expression of CD200 and INSM1 in gastrointestinal and pancreatic neuroendocrine neoplasms and its diagnostic values].
Cao Z; Cen HB; Wei JG; Qin LZ; Liao W; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2021 Oct; 50(10):1134-1138. PubMed ID: 34619866
[No Abstract] [Full Text] [Related]
15. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms cga and has surgical and clinical utility.
Modlin IM; Kidd M; Falconi M; Filosso PL; Frilling A; Malczewska A; Toumpanakis C; Valk G; Pacak K; Bodei L; Öberg KE
Ann Oncol; 2021 Nov; 32(11):1425-1433. PubMed ID: 34390828
[TBL] [Abstract] [Full Text] [Related]
16. Use of Chromogranin A for Monitoring Patients With pancreatic Neuroendocrine Neoplasms.
Yu F; Fu J; Zhang C; Wu W; Ai S; Yao X; Meng Q; Huang Y; Lu G; Wang F; Qu W
Pancreas; 2021 Jul; 50(6):882-889. PubMed ID: 34347728
[TBL] [Abstract] [Full Text] [Related]
17. mRNA profiling of a well-differentiated G1 pancreatic NET correlates with immunohistochemistry profile: a case report.
Venugopal A; Gillick-Walker J; Michalczyk A; Khasraw M; Ackland ML
BMC Gastroenterol; 2021 Apr; 21(1):194. PubMed ID: 33906633
[TBL] [Abstract] [Full Text] [Related]
18. Basics for surgeons about the immunohistochemistry role in pancreatic NETs diagnosis.
Romano L; Giuliani A; Vicentini V; Schietroma M; Carlei F
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2548-2553. PubMed ID: 33829441
[TBL] [Abstract] [Full Text] [Related]
19. Risk factors for progression of appendiceal neuroendocrine tumours: low-stage tumours <5 mm appear to be overwhelmingly indolent and may merit a separate designation.
Noor M; Huber AR; Cates JMM; Gonzalez RS
Histopathology; 2021 Sep; 79(3):416-426. PubMed ID: 33754384
[TBL] [Abstract] [Full Text] [Related]
20. Thymic Carcinoid as the First Manifestation of Multiple Endocrine Neoplasia Type 1 Syndrome: A Case Report and Review of the Literature.
Zheng M; Chen S; Qi C; Ren L; Zhen Y; Yu X; Wei L
Ann Clin Lab Sci; 2020 Nov; 50(6):825-833. PubMed ID: 33334800
[TBL] [Abstract] [Full Text] [Related]
[Next]
